Efficacy and tolerability of certolizumab pegol in Crohn's disease in clinical practice.

Aim: To assess the efficacy and tolerance of certolizumab pegol (CP) in patients with Crohn's disease (CD) treated in the Department of inflammatory bowel diseases of the A.S. Loginov Moscow Clinical Research Center and to determine the predictors of response to therapy.

[Clinical and morphological variants of diverticular disease in colon].

Our own results of two-stage research are presented in the article. The first stage contains the retrospective analysis of 3682 X-ray examining of large bowel which were conducted in 2002-2004 to define the structure of colon disease and to determine gender differences. The second stage is prospective research which took place from 2003 to 2012 and 486 patients with diverticular disease were regularly observed.

Regeneration of colorectal epithelium in diverticulosis.

Excessive poorly differentiated epitheliocytes were detected in the crypts and subepithelial regions of the colorectal mucosa during the regeneration process in the majority of patients with diverticular disease. The compensatory reaction of the sigmoid mucosa decreased, which was seen from rarely detected cryptic hyperplasia. Disorders in the epitheliocyte proliferation and differentiation were paralleled by changes in tissue levels of proinflammatory cytokines (elevation of TNF-α and IFN-γ and reduction of IL-1β and IL-8) and increase of IL-4, regulating lymphocyte activation.

[External respiratory function in patients with Crohn's disease].

This article presents the results of a study of respiratory function (SRF) in 56 patients with Crohn's disease (CD) who were hospitalized in the Department of intestine pathology in Central research institute of gastroenterology. SRF was determined by spirography and registration of the curve flow--volume forced exhale ("Eton-1, RF). Violations of pulmonary function in CD occurred in 44.